P4, N=644, Not yet recruiting, Chiesi Farmaceutici S.p.A.

P4, N=182, Not yet recruiting, Montefiore Medical Center | Trial completion date: Sep 2026 --> Dec 2026 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Sep 2026 --> Dec 2026

P3, N=90, Not yet recruiting, The University of Hong Kong

E4BP4 promotes MM progression by upregulating HDAC3, reducing histone acetylation and Beclin1 transcription to suppress autophagy/apoptosis. Its role in dexamethasone resistance highlights E4BP4 as a potential therapeutic target.

Stereotactic brain biopsy confirmed PCNSL, and the patient was initiated on high-dose methotrexate-based chemotherapy with adjunctive dexamethasone. This case highlights that PCNSL can occur despite immunologic preservation in HIV and may present acutely with seizures. Early contrast-enhanced MRI, careful timing of corticosteroid use relative to biopsy, and timely referral are essential, particularly in resource-limited settings.

P=N/A, N=65, Not yet recruiting, University of California, Davis

Further, to establish mAb ASGPR1-mediated drug delivery, an anti-inflammatory drug dexamethasone (DEX) was conjugated to mAb ASGPR1 through an ester linker generating mAb ASGPR1-DEX ADC...The mAb ASGPR1-DEX conjugate exhibited significant efficacy against lipopolysaccharide-induced hepatic inflammation by attenuating levels of interleukin-6, interleukin-1beta, and tumor necrosis factor in mouse precision cut liver slices and hepatocyte organoids. Collectively, these findings hold significant implications for mAb ASGPR1-based ADC as a promising therapeutic modality that warrants further investigation in inflammation-induced liver pathologies.

This study presents a long-acting hybrid dissolving microneedle (DMN) patch incorporating hyaluronic acid (HA)-based microparticle depots (TA@MDepots) for intradermal delivery of triamcinolone acetonide (TA)...Histological analyses confirm skin structure restoration and immune modulation, while systemic toxicity assessments show no adverse effects. This hybrid DMN platform offers a minimally invasive, biocompatible, and patient-friendly strategy for prolonged corticosteroid delivery in chronic inflammatory skin diseases and represents a promising alternative to conventional topical or injectable therapies.

P4, N=1, Terminated, Weill Medical College of Cornell University | Active, not recruiting --> Terminated; The study was terminated due to slow accrual.

P=N/A, N=200, Recruiting, Chulalongkorn University | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Nov 2026

P3, N=276, Recruiting, Erasmus Medical Center

Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.